Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leukemija, limfocitinė, lėtinė, b-ląstelė - antinavikiniai vaistai - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

glaxosmithkline trading services limited - salbutamolis - sirupas - 2 mg/5 ml - salbutamol

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

glaxosmithkline trading services limited - salbutamolis - purškiamasis įkvepiamasis tirpalas - 100 µg/išpurškime; 500 µg/ml; 2,5 mg/2,5 ml - salbutamol

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

lex ano, uab - salbutamolis - purškiamasis įkvepiamasis tirpalas - 2,5 mg/2,5 ml - salbutamol

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

lex ano, uab - salbutamolis - purškiamasis įkvepiamasis tirpalas - 2,5 mg/2,5 ml - salbutamol

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

lex ano, uab - salbutamolis - sirupas - 2 mg/5 ml - salbutamol

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

tojaris projektai, uab - salbutamolis - sirupas - 2 mg/5 ml - salbutamol

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

lex ano, uab - salbutamolis - injekcinis tirpalas - 500 µg/ml - salbutamol

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

lex ano, uab - salbutamolis - sirupas - 2 mg/5 ml - salbutamol